CNS cancer immunity cycle and strategies to target this for glioblastoma
Metrics: PDF 1318 views | HTML 1837 views | ?
Malaka Ameratunga1, Niamh Coleman1, Liam Welsh2, Frank Saran2 and Juanita Lopez1
1Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK
2Department of Neuro-Oncology, Royal Marsden Hospital and The Institute of Cancer Research, Sutton SM2 5PT, UK
Juanita Lopez, email: email@example.com
Keywords: glioblastoma; immunotherapy; cancer-immunity cycle; checkpoint inhibitors; clinical trials
Received: November 30, 2017 Accepted: March 11, 2018 Published: April 27, 2018
Immunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of the central nervous system (CNS) has been lacking. There are several possible reasons for the relative lack of success of immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system and impairment of drug delivery into the CNS through the BBB. This review utilizes the cancer-immunity cycle as a conceptual framework through which the specific challenges associated with the development of immunotherapeutics for CNS malignancies can be viewed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.